Why the study?
To ascertain whether patients with Brugada syndrome harboring SCN5A mutations have a more severe clinical phenotype and prognosis than those without SCN5A mutations.
Do SCN5A mutations predict a more severe clinical phenotype and prognosis in patients with Brugada syndrome compared to those without?
Population
Patients with Brugada syndrome
Comparison
Presence of SCN5A mutations vs absence of SCN5A mutations
Design
Comprehensive literature review
Key result
SCN5A mutations in Brugada syndrome weakly predict greater malignant arrhythmic event risk and electrophysiological abnormalities, but lack robust associations for independent risk stratification.
Authors
Loading...
SCN5A testing should not guide Brugada risk stratification; leaves open whether larger prospective studies can establish independent prognostic value.
Do SCN5A mutations predict a more severe clinical phenotype and prognosis in patients with Brugada syndrome compared to those without?
While SCN5A mutations in Brugada syndrome are associated with greater electrophysiological abnormalities and weakly predict malignant arrhythmias, they are currently insufficient as independent risk stratification tools.
Deica et al. (2022) conducted a review in Brugada syndrome. SCN5A mutations vs. Without SCN5A mutations was evaluated on Phenotype severity and prognosis. SCN5A mutations in Brugada syndrome weakly predict greater malignant arrhythmic event risk and electrophysiological abnormalities, but lack robust associations for independent risk stratification.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: